ClinicalTrials.gg
CompletedNCT00660010Updated Apr 12, 2011Results posted

Study of Lupron Depot In The Treatment of Central Precocious Puberty

A Phase 3 interventional study of Lupron (leuprolide acetate) in Puberty, Precocious, sponsored by Abbott. Completed at 9 sites in United States. Open to participants aged Up to 10 Years. Per ClinicalTrials.gov, last updated 2011-04-12.

Sponsored by Abbott · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
Up to 10 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies testing leuprolide in Puberty, Precocious — 2 open to participants now, 2 under way, 1 of them phase 3. Leuprolide · Puberty, Precocious.

Enrollment
10th of 14
55 · median 68
Started
1991
the only one that year
Phase 3
6 of 14
1 open now
Registered
2nd of 14
by date
Lead sponsor
2 of 14
Abbott

Among the 14 studies testing leuprolide in Puberty, Precocious, this one is the 10th largest by enrollment, is the only one that started in 1991, is one of 6 in phase 3, and was the 2nd registered.

Puberty, Precocious

75 studies on the registry are indexed under Puberty, Precocious; 18 are open to participants now.

Browse Puberty, Precocious studies →

Open to participants now

2 of the 14 studies testing leuprolide in Puberty, Precocious are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About leuprolide

Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Puberty, Precocious studies recruiting now, 2 (14%) set no upper age limit and 9 (64%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: Up to 10 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing leuprolide in Puberty, Precocious, or all of them as a file.
02

Study summary

The purpose of this study is to determine if Lupron (leuprolide acetate) is safe and effective in treating children with Central Precocious Puberty (CPP), and to assess long term effects of leuprolide acetate treatment after therapy is discontinued.

Read the detailed description

This study includes a Prestudy Period; a treatment period where subjects will receive treatment every 4 weeks until the initiation of puberty (age 12 for males and age 11 for females); a follow-up period where subjects will be observed every 6 months until physical and laboratory observations are at pubertal levels, then every 12 months for 5 years; lastly a final follow-up questionnaire is given to all subjects when they are at least 18 years old.

At the treatment visits, efficacy assessments are Tanner staging (suppression of breast development in females and genital development in males), gonadotropins (LH and FSH), sex steroids (estradiol in females and testosterone in males), ratio of bone age to chronological age, adult height compared to a standard population and predicted mature height, and age and time to regular menses in females. This protocol will also capture data from the final questionnaire about female reproductive status at adulthood including the presence of regular menses and number of pregnancies.

03

Conditions studied

  • Puberty, Precocious

Browse trials for

Keywords

  • CPP
  • central precocious puberty
  • pediatrics
  • suppression of LH
  • Lupron
  • leuprolide acetate
  • depot formulation
  • GnRHa
  • GnRH agonist
  • GNRH analog
  • LH
  • Tanner staging
04

Who can participate

Ages eligible
Up to 10 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of isosexual central precocious puberty with onset of Tanner scores of Stage II for breast or pubic hair earlier than age 8.0 years in girls or Stage II for pubic hair or genitalia earlier than 9.0 years in boys.
  • Confirmation of diagnosis by a pubertal response to a gonadotropin-releasing hormone (GnRH) stimulation test (LH > 10 U/L at baseline).
  • Chronological age less than 9.0 years in girls or less than 10.0 years in boys at time of first dosing.
  • Bone age advanced at least 1 year beyond the chronological age at entry into the study.
  • The condition may be idiopathic or secondary to another lesion. If secondary, therapy of the primary condition will have been undertaken and stabilized.
  • No evidence of abnormal pituitary, adrenal, thyroid and gonadal function except for premature secretion of gonadotropins.

Exclusion criteria

Exclusion Criteria:

  • Irradiation to the central nervous system.
  • Prior therapy with medroxyprogesterone acetate and/or with any GnRH analog (including prior treatment with daily subcutaneous and depot formulations of leuprolide acetate).
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    1

    Drug: Lupron (leuprolide acetate)

Interventions

  • Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.

    Also known as: Lupron

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)

    Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).

    Time frame: Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit

  2. Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)

    Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).

    Time frame: Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit

Secondary outcomes

  1. Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations

    Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.

    Time frame: Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit

  2. Mean Stimulated Estradiol Concentrations in Females

    Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.

    Time frame: Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit

  3. Mean Stimulated Testosterone Concentrations in Males

    Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.

    Time frame: Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit

  4. Mean Ratio of Bone Age to Chronological Age

    Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.

    Time frame: Week 24 and Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit

Other outcomes

  1. Posttreatment Height (ht.) Compared to Standard Population and as Predicted From Ht. at Baseline (BL)

    Height was measured by stadiometer and was standardized for age according to standard growth charts. A standardized score of 0 indicated a mean ht. equivalent to mean of a standard population from 2000 CDC standardized ht. charts. Height gain was calculated as ht. - predicted ht. from the Bayley-Pinneau method on the basis of bone age at baseline. Final adult ht. was determined by measurement at final adult ht., if available, or by ht. collected during the follow-up period associated with a growth velocity \<1 cm/year or a bone age \>14 yrs in females or \>15 yrs in males.

    Time frame: Final ht. (measured or provided for final questionnaire in subjects >= 18 years of age) or near final adult ht. (<1 cm/year or bone age > 14 years for females or > 15 years for males)

  2. Mean Time to or Mean Age at Regular Menses in Females After Treatment

    Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding and was defined by the investigator's clinical judgment.

    Time frame: Posttreatment during the follow-up period (subjects observed every 6 months until physical and laboratory observations are at pubertal levels)

  3. Number of Female Subjects Who Reported Regular Menses at Adulthood

    Subjects were required to complete final adult questionnaire to provide information on adult reproductive function. Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding.

    Time frame: Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)

  4. Number of Subjects Who Reported Pregnancies at Final Questionnaire

    The final questionnaire was completed by 20 females who were at least 18 years of age. The subjects reported on total number of pregnancies resulting in live births or number of miscarriages (spontaneous or elective) and whether the subject was currently pregnant.

    Time frame: Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)

  5. Number of Pregnancies Reported by Subjects at Final Questionnaire

    The final questionnaire was completed by 20 female subjects who were at least 18 years of age. The total number of pregnancies were reported.

    Time frame: Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)

07

Results

Posted Jul 20, 2010
Limitations and caveats
Study drug was discontinued usually at the initiation of puberty (12 years for males and 11 years for females) with the concurrence of the investigator, or at the discretion of the investigator. Adverse events are coded with the COSTART dictionary.

Participant flow

Participant flow — Overall Study
MilestoneLeuprolide Acetate 1 Month Depot
Started55
Completed46
Not completed9
Withdrew: Withdrawal by subject2
Withdrew: Lost to follow-up3
Withdrew: Adverse event1
Withdrew: Noncompliance with visit schedule3

Outcome measures

PrimaryPercentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)

Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of breast development in females. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of breasts. The final visit occurred at a mean age +/- SD of 11.05 +/- 1.14 years (range, 6.96 to 12.95 years).

Time frame:
Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Reported as:
Number · Percentage of subjects
Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Breast Development in Females)
Percentage of subjectsLeuprolide Acetate 1 Month Depot
Breast development suppression - Week 4 N=4481.8
Breast development suppression-Week 48 N=4780.9 (66.7 to 90.9)
Breast development suppression -Week 96 N=4187.8 (73.8 to 95.9)
Breast development suppression-Week 144 N=2982.8 (64.2 to 94.2)
Breast development suppression - Week 192 N=1866.7 (41.0 to 86.7)
Breast development suppression -Week 240 N=1376.9 (46.2 to 95.0)
Breast development suppression-Final Visit N=4877.1
SecondaryMean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations

Mean peak stimulated visit LH and FSH concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of both hormone concentrations occurred at a mean age +/- SD of 11.13 +/- 1.23 (range, 6.73 to 14.07) years.

Time frame:
Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Reported as:
Mean · mIU/mL
Mean Peak Stimulated Luteinizing Hormone (LH) and Follicle Stimulating Hormone (FSH) Concentrations
mIU/mLLeuprolide Acetate 1 Month Depot
Peak stimulated LH at Baseline N=5535.0 ± 21.32
Peak stimulated LH at Week 4 N = 550.8 ± 0.57
Peak stimulated LH at Week 12 N = 541.1 ± 1.77
Peak stimulated LH at Week 24 N = 530.8 ± 0.79
Peak stimulated LH at Week 48 N = 540.6 ± 0.47
Peak stimulated LH at Week 96 N = 460.4 ± 0.33
Peak stimulated LH at Week 144 N = 360.4 ± 0.24
Peak stimulated LH at Week 192 N = 200.4 ± 0.25
Peak stimulated LH at Week 240 N = 170.4 ± 0.62
Peak stimulated LH at Final Visit N = 550.8 ± 3.29
Peak stimulated FSH at Baseline N=5513.3 ± 5.58
Peak stimulated FSH at Week 4 N = 550.9 ± 0.44
Peak stimulated FSH at Week 12 N = 541.1 ± 0.61
Peak stimulated FSH at Week 24 N = 531.2 ± 0.84
Peak stimulated FSH at Week 48 N = 541.2 ± 0.58
Peak stimulated FSH at Week 96 N = 461.4 ± 0.79
Peak stimulated FSH at Week 144 N = 361.4 ± 0.73
Peak stimulated FSH at Week 192 N = 201.3 ± 0.76
Peak stimulated FSH at Week 240 N = 171.4 ± 0.67
Peak stimulated FSH at Final Visit N = 551.7 ± 1.73
SecondaryMean Stimulated Estradiol Concentrations in Females

Mean estradiol concentrations were assessed according to the DELFIA (registered trademark) assay. The lower limit of quantitation for estradiol is 5 pg/mL and measurements below this limit are given a value of 5 pg/mL. The final visit for measurement estradiol concentrations occurred at a mean age +/- SD of 10.93 +/- 1.27 (range, 5.59 to 13.24) years.

Time frame:
Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Reported as:
Mean · pg/mL
Mean Stimulated Estradiol Concentrations in Females
pg/mLLeuprolide Acetate 1 Month Depot
Mean stimulated estradiol at baseline N=4915.3 ± 18.73
Mean stimulated estradiol at Week 4 N=485.0 ± 0.00
Mean stimulated estradiol at Week 12 N=476.0 ± 6.56
Mean stimulated estradiol at Week 24 N=475.0 ± 0.00
Mean stimulated estradiol at Week 48 N=475.0 ± 0.00
Mean stimulated estradiol at Week 96 N=395.0 ± 0.00
Mean stimulated estradiol at Week 144 N=315.0 ± 0.00
Mean stimulated estradiol at Week 192 N=155.0 ± 0.00
Mean stimulated estradiol at Week 240 N=135.0 ± 0.00
Mean stimulated estradiol at Final Visit N=495.0 ± 0.14
SecondaryMean Stimulated Testosterone Concentrations in Males

Mean stimulated testosterone concentrations were assessed according to the DELFIA (registered trademark) assay. The final visit for measurement of testosterone occurred at a mean age +/- SD of 12.34 +/- 1.16 (range, 11.14 to 14.07) years.

Time frame:
Baseline, Weeks 4, 12, 24, 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Reported as:
Mean · ng/dL
Mean Stimulated Testosterone Concentrations in Males
ng/dLLeuprolide Acetate 1 Month Depot
Mean stimulated testosterone at baseline N=6347.7 ± 121.86
Mean stimulated testosterone at Week 4 N=618.0 ± 12.39
Mean stimulated testosterone at Week 12 N=614.2 ± 7.05
Mean stimulated testosterone at Week 24 N=613.8 ± 6.15
Mean stimulated testosterone at Week 48 N=617.3 ± 11.64
Mean stimulated testosterone at Week 96 N=624.8 ± 19.92
Mean stimulated testosterone at Week 144 N=521.6 ± 19.50
Mean stimulated testosterone at Week 192 N=424.0 ± 17.19
Mean stimulated testosterone at Week 240 N=325.3 ± 24.01
Mean stimulated testosterone at Final Visit N=624.2 ± 17.16
SecondaryMean Ratio of Bone Age to Chronological Age

Bone age was determined by radiography of the wrist according to the Fels Method. The mean ratio of bone age to chronological age provides information about the slowing of bone age progression. A score = 1 indicates that bone age is equal to chronological age.

Time frame:
Week 24 and Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Reported as:
Mean · ratio
Mean Ratio of Bone Age to Chronological Age
ratioLeuprolide Acetate 1 Month Depot
Ratio at Baseline N=531.5 ± 0.30
Ratio at Week 24 N=531.5 ± 0.25
Ratio at Week 48 N=511.4 ± 0.18
Ratio at Week 96 N=441.3 ± 0.15
Ratio at Week 144 N=311.2 ± 0.12
Ratio at Week 192 N=261.2 ± 0.11
Ratio at Week 240 N=161.2 ± 0.10
Ratio at Final Visit N=531.2 ± 0.11
Other pre-specifiedPosttreatment Height (ht.) Compared to Standard Population and as Predicted From Ht. at Baseline (BL)

Height was measured by stadiometer and was standardized for age according to standard growth charts. A standardized score of 0 indicated a mean ht. equivalent to mean of a standard population from 2000 CDC standardized ht. charts. Height gain was calculated as ht. - predicted ht. from the Bayley-Pinneau method on the basis of bone age at baseline. Final adult ht. was determined by measurement at final adult ht., if available, or by ht. collected during the follow-up period associated with a growth velocity \<1 cm/year or a bone age \>14 yrs in females or \>15 yrs in males.

Time frame:
Final ht. (measured or provided for final questionnaire in subjects >= 18 years of age) or near final adult ht. (<1 cm/year or bone age > 14 years for females or > 15 years for males)
Reported as:
Mean · cm
Posttreatment Height (ht.) Compared to Standard Population and as Predicted From Ht. at Baseline (BL)
cmLeuprolide Acetate 1 Month Depot
Near final adult ht. standardized score N=33-0.2 ± 1.20
Near final ht.gain from predicted ht. at BL N=293.2 ± 5.37
Final adult ht.standardized score N=190.0 ± 1.13
Final adult ht.gain from predicted ht. at BL N=173.9 ± 5.05
Other pre-specifiedMean Time to or Mean Age at Regular Menses in Females After Treatment

Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding and was defined by the investigator's clinical judgment.

Time frame:
Posttreatment during the follow-up period (subjects observed every 6 months until physical and laboratory observations are at pubertal levels)
Reported as:
Mean · years
Mean Time to or Mean Age at Regular Menses in Females After Treatment
yearsLeuprolide Acetate 1 Month Depot
Time to regular menses1.5 ± 0.53
Age at regular menses12.9 ± 0.89
Other pre-specifiedNumber of Female Subjects Who Reported Regular Menses at Adulthood

Subjects were required to complete final adult questionnaire to provide information on adult reproductive function. Regular menses was defined as 3 or more consecutive days of menstrual-like bleeding.

Time frame:
Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)
Reported as:
Number · Subjects
Number of Female Subjects Who Reported Regular Menses at Adulthood
SubjectsLeuprolide Acetate 1 Month Depot
No. of subjects with regular menses as adults16
No. of subjects without regular menses as adults4
Other pre-specifiedNumber of Subjects Who Reported Pregnancies at Final Questionnaire

The final questionnaire was completed by 20 females who were at least 18 years of age. The subjects reported on total number of pregnancies resulting in live births or number of miscarriages (spontaneous or elective) and whether the subject was currently pregnant.

Time frame:
Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)
Reported as:
Number · Subjects
Number of Subjects Who Reported Pregnancies at Final Questionnaire
SubjectsLeuprolide Acetate 1 Month Depot
Number of subjects who reported being pregnant7
Number of subjects who were currently pregnant1
Other pre-specifiedNumber of Pregnancies Reported by Subjects at Final Questionnaire

The final questionnaire was completed by 20 female subjects who were at least 18 years of age. The total number of pregnancies were reported.

Time frame:
Posttreatment data were collected from the final adult questionnaire (subjects >= 18 years of age)
Reported as:
Number · Pregnancies
Number of Pregnancies Reported by Subjects at Final Questionnaire
PregnanciesLeuprolide Acetate 1 Month Depot
Number of pregnancies12
Number of live births6
Number of miscarriages5
PrimaryPercentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)

Suppression of clinical sexual characteristics was defined as regression (improvement) or no progression of genital development in males. Tanner staging is a scale of physical development that defines primary and secondary sex characteristics including size of genitals. The final visit occurred at a mean age +/- SD of 12.35 +/-1.35 years (range, 10.71 to 14.07 years).

Time frame:
Week 4, Week 48 (Year 1), yearly for 5 years (Week 240), and Final Visit
Reported as:
Number · Percentage of subjects
Percentage of Subjects (n/N) With Suppression of Clinical Sexual Characteristics According to Tanner Staging (Genital Development in Males)
Percentage of subjectsLeuprolide Acetate 1 Month Depot
Genital development suppression - Week 4 N=580.0
Genital development suppression - Week 48 N=683.3
Genital development suppression - Week 96 N=683.3
Genital development suppression - Week 144 N=475.0
Genital development suppression - Week 192 N=475.0
Genital development suppression - Week 240 N=366.7
Genital development suppression - Final Visit N=683.3

Adverse events

Collected over Each investigator monitored each subject for clinical and laboratory evidence of adverse events at Weeks 4, 8, 12, 24, 36, 48, and then every 6 months until the study drug was discontinued.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Leuprolide Acetate 1 Month Depot—7/55 (12.7%)52/55 (94.5%)
Most frequent serious events
Most frequent serious events
EventLeuprolide Acetate 1 Month Depot
Aggravation reactionGeneral disorders1/55
CarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/55
InfectionInfections and infestations1/55
Heart arrestCardiac disorders1/55
Bone DisorderMusculoskeletal and connective tissue disorders1/55
Pathological fractureMusculoskeletal and connective tissue disorders1/55
Personality disorderPsychiatric disorders1/55
AsthmaRespiratory, thoracic and mediastinal disorders1/55
PneumoniaInfections and infestations1/55
Repair of ventriculoperitoneal shuntSurgical and medical procedures1/55
Most frequent other events
Showing 10 of 50
Most frequent other events
EventLeuprolide Acetate 1 Month Depot
PharyngitisInfections and infestations29/55
HeadacheNervous system disorders25/55
Flu syndromeInfections and infestations19/55
RashSkin and subcutaneous tissue disorders18/55
Cough increasedRespiratory, thoracic and mediastinal disorders17/55
Abdominal painGastrointestinal disorders16/55
Accidental injuryInjury, poisoning and procedural complications16/55
Emotional LabilityPsychiatric disorders15/55
AcneSkin and subcutaneous tissue disorders15/55
Otitis mediaInfections and infestations15/55

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Leuprolide Acetate 1 Month Depot
<=18 years55
Between 18 and 65 years0
>=65 years0
Age Continuous
Age Continuous(years)Leuprolide Acetate 1 Month Depot
Mean6.9 ± 1.86
Sex: Female, Male
Sex: Female, Male(Participants)Leuprolide Acetate 1 Month Depot
Female49
Male6
Region of Enrollment
Region of Enrollment(subjects)Leuprolide Acetate 1 Month Depot
United States55
08

Study locations

9 sites
  • Site Reference ID/Investigator# 46673
    Phoenix, Arizona 85006, United States
  • Site Reference ID/Investigator# 46671
    San Francisco, California 94122, United States
  • Site Reference ID/Investigator# 14921
    Stanford, California 94305, United States
  • Site Reference ID/Investigator# 14343
    Aurora, Colorado 80045, United States
  • Site Reference ID/Investigator# 14341
    St. Petersburg, Florida 33701, United States
  • Site Reference ID/Investigator# 14342
    Indianapolis, Indiana 46202, United States
  • Site Reference ID/Investigator# 46672
    Baltimore, Maryland 21201, United States
  • Site Reference ID/Investigator# 46668
    Springfield, Massachusetts 01199, United States
  • Site Reference ID/Investigator# 14344
    Hershey, Pennsylvania 17033, United States
09

References and documents

Publications

  • Lee PA, Neely EK, Fuqua J, Yang D, Larsen LM, Mattia-Goldberg C, Chwalisz K. Efficacy of Leuprolide Acetate 1-Month Depot for Central Precocious Puberty (CPP): Growth Outcomes During a Prospective, Longitudinal Study. Int J Pediatr Endocrinol. 2011;2011(1):7. doi: 10.1186/1687-9856-2011-7. Epub 2011 Jul 12. PubMed 21860633 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 1991, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2010, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 15, 2008
First posted
Apr 17, 2008
Start
Jan 1991
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Results first posted
Jul 20, 2010
Last update
Apr 12, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00660010
Lead sponsor
Abbott
First posted
Apr 17, 2008
Start date
Jan 1991
Primary completion
Apr 2009
Completion
Apr 2009
Results posted
Jul 20, 2010
Last update
Apr 12, 2011

Study contacts

Kristof Chwalisz, MD
study director · Abbott

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Leuprolide

Start the discussion